Published in Drug Week, March 31st, 2006
Under the agreement Artemis will generate various genetically-engineered murine models carrying selected genetic mutations. Bristol-Myers Squibb will use these models in its drug discovery research activities for the validation of novel drug screening targets. Such targets are used to identify new compounds and therapies for the treatment of diseases for various indications in humans. In vivo validation of disease-related drug targets and data generated from them are increasingly considered to be vital for the success of innovative drug discovery...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.